Donanemab in Early Alzheimer’s Disease

Abstract

In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).

Keywords

DiseaseMedicineInternal medicine

MeSH Terms

Activities of Daily LivingAdministrationIntravenousAgedAlzheimer DiseaseBrain EdemaCognitionDisease ProgressionDouble-Blind MethodEpitopesFemaleHumansMaleMental Status and Dementia TestsPlaqueAmyloidPyrrolidonecarboxylic AcidSeverity of Illness Index

Affiliated Institutions

Related Publications

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck , Chad J. Swanson , Paul Aisen +16 more

Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was...

2022 New England Journal of Medicine 4288 citations

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies

Gene E. Alexander , Kewei Chen , Pietro Pietrini +2 more

These findings indicate that brain metabolism as assessed by FDG PET during mental rest is a sensitive marker of disease progression in Alzheimer's disease over a 1-year period....

2002 American Journal of Psychiatry 518 citations

The Familial Transmission of Bipolar Illness

John P. Rice , Theodore Reich , Nancy C. Andreasen +5 more

As part of the National Institute of Mental Health Collaborative Program on the Psychobiology of Depression study, data were collected on 2225 first-degree relatives of 612 prob...

1987 Archives of General Psychiatry 356 citations

Mild cognitive impairment as a diagnostic entity

Ronald C. Petersen

Abstract. The concept of cognitive impairment intervening between normal ageing and very early dementia has been in the literature for many years. Recently, the construct of mil...

2004 Journal of Internal Medicine 7591 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 18
Pages: 1691-1704
Citations: 1451
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Donanemab in Early Alzheimer’s Disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1451

OpenAlex

Influential

1300

CrossRef

Cite This

APA Style

                            
                                
                                    Mark A. Mintun, 
                                
                                    Albert Lo, 
                                
                                    Cynthia Evans
                                
                                et al.
                            
                            (2021). 
                            Donanemab in Early Alzheimer’s Disease. 
                            New England Journal of Medicine
                            , 384
                            (18)
                            , 1691-1704.
                            https://doi.org/10.1056/nejmoa2100708
                        

Identifiers

DOI: 10.1056/nejmoa2100708
PMID: 33720637

Data Quality

Data completeness: 90%